Factors affecting the success of intravesical onabotulinum toxin A injection in the treatment of refractory idiopathic overactive bladder.

IF 0.8 Q4 UROLOGY & NEPHROLOGY

Urologia Journal Pub Date : 2025-04-23 DOI:10.1177/03915603251334081

Recep Burak Degirmentepe, Mehmet Gokhan Culha, Musab Umeyir Karakanli, Kenan Sabuncu, Emre Can Polat, Caner Baran, Alper Otunctemur

{"title":"Factors affecting the success of intravesical onabotulinum toxin A injection in the treatment of refractory idiopathic overactive bladder.","authors":"Recep Burak Degirmentepe, Mehmet Gokhan Culha, Musab Umeyir Karakanli, Kenan Sabuncu, Emre Can Polat, Caner Baran, Alper Otunctemur","doi":"10.1177/03915603251334081","DOIUrl":null,"url":null,"abstract":"Background: Onabotulinum toxin A injection is recommended for overactive bladder (OAB) resistant to medical treatments. However, success is not universal, and factors influencing outcomes remain unclear. This study evaluates the factors affecting the success of onabotulinum toxin A injection in refractory idiopathic OAB.Methods: Data from patients with resistant idiopathic OAB treated with 100 IU onabotulinum toxin A (BOTOX®, Allergan, Dublin, Ireland) between January 2019 and August 2023 were analyzed. Demographic data and symptom duration were recorded. Patients were evaluated pre- and post-procedure using the overactive bladder symptom score (OABSS) and 3-day bladder diaries. A ⩾50% improvement in OABSS was considered treatment success. Botox was injected at 20 sites (5 IU per site) via 22 Fr rigid cystoscope under sedoanalgesia.Results: A total of 210 patients (80.5% female, n = 169) with a mean age of 53.76 ± 14.90 years were included. Symptom duration averaged 39.82 ± 22.28 months. Wet OAB was diagnosed in 83.3% (n = 175), while 16.7% (n = 35) had dry OAB. Pre-procedure mean OABSS was 9.18 ± 1.31, daily micturition 8.67 ± 1.52, urge incontinence 2.57 ± 1.28, nocturia 1.87 ± 0.75, and pad use 2.44 ± 1.24/day. Treatment success was achieved in 82.4% (n = 173).Conclusion: The degree of patient complaints, particularly daily micturition frequency, significantly affects treatment success. Patients with higher daily micturition may require advanced interventions beyond Botox.","PeriodicalId":23574,"journal":{"name":"Urologia Journal","volume":" ","pages":"3915603251334081"},"PeriodicalIF":0.8000,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urologia Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/03915603251334081","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Onabotulinum toxin A injection is recommended for overactive bladder (OAB) resistant to medical treatments. However, success is not universal, and factors influencing outcomes remain unclear. This study evaluates the factors affecting the success of onabotulinum toxin A injection in refractory idiopathic OAB.

Methods: Data from patients with resistant idiopathic OAB treated with 100 IU onabotulinum toxin A (BOTOX^®, Allergan, Dublin, Ireland) between January 2019 and August 2023 were analyzed. Demographic data and symptom duration were recorded. Patients were evaluated pre- and post-procedure using the overactive bladder symptom score (OABSS) and 3-day bladder diaries. A ⩾50% improvement in OABSS was considered treatment success. Botox was injected at 20 sites (5 IU per site) via 22 Fr rigid cystoscope under sedoanalgesia.

Results: A total of 210 patients (80.5% female, n = 169) with a mean age of 53.76 ± 14.90 years were included. Symptom duration averaged 39.82 ± 22.28 months. Wet OAB was diagnosed in 83.3% (n = 175), while 16.7% (n = 35) had dry OAB. Pre-procedure mean OABSS was 9.18 ± 1.31, daily micturition 8.67 ± 1.52, urge incontinence 2.57 ± 1.28, nocturia 1.87 ± 0.75, and pad use 2.44 ± 1.24/day. Treatment success was achieved in 82.4% (n = 173).

Conclusion: The degree of patient complaints, particularly daily micturition frequency, significantly affects treatment success. Patients with higher daily micturition may require advanced interventions beyond Botox.

查看原文本刊更多论文

膀胱内注射A型肉毒杆菌毒素治疗难治性特发性膀胱过动症成功的影响因素。

背景：对药物治疗耐药的膀胱过度活动症（OAB）推荐注射A肉毒杆菌毒素。然而，成功并不是普遍的，影响结果的因素仍不清楚。本研究评价影响A型肉毒杆菌毒素注射治疗难治性特发性OAB成功的因素。方法：分析2019年1月至2023年8月期间接受100 IU肉毒杆菌毒素A （BOTOX®，Allergan, Dublin, Ireland）治疗的耐药特发性OAB患者的数据。记录人口学数据和症状持续时间。使用膀胱过度活动症状评分（OABSS）和3天膀胱日记对患者进行术前和术后评估。OABSS改善大于或等于50%被认为是治疗成功。在麻醉下，通过22 Fr刚性膀胱镜在20个部位注射肉毒杆菌素（每个部位5 IU）。结果：共纳入210例患者，其中女性80.5%,n = 169例，平均年龄53.76±14.90岁。症状持续时间平均39.82±22.28个月。湿性OAB占83.3% (n = 175)，干性OAB占16.7% （n = 35）。术前平均OABSS为9.18±1.31，日排尿8.67±1.52，急迫性尿失禁2.57±1.28，夜尿1.87±0.75，尿垫使用2.44±1.24/d。治疗成功率为82.4% （n = 173）。结论：患者的主诉程度，尤其是每日排尿次数对治疗成功率有显著影响。每日排尿较多的患者可能需要除肉毒杆菌外的高级干预措施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Urologia Journal UROLOGY & NEPHROLOGY-

CiteScore

0.60

自引率

12.50%

发文量